View Published SNOMED CT Subset Metadata

QOF NICE recommended prescribable bone sparing agents


Subset Name :   
QOF NICE recommended prescribable bone sparing agents
Subset Original Id :   
635401000001139
Subset Type :   
Realm Concept

Refset FSN :   
Quality and Outcomes Framework general practice extraction - bone sparing agents prescribable within general practice simple reference set (foundation metadata concept)
Refset Id :   
12465701000001102
Refset Type :   
Simple

Subset Description :
All VMPs and AMPs associated with the following VTMs: Parathyroid hormone, Etidronate disodium, Risedronate sodium, Zoledronic acid, Ibandronic acid, Teriparatide, Raloxifene, Alendronic acid, Alendronic acid + Colecalciferol, Strontium ranelate and Denosumab. The following VMPs and their associated AMPs Calcium carbonate 1.25g effervescent tablets and Disodium etidronate 400mg tablets Generic Actonel Combi 35mg tablets and 1000mg/880unit effervescent granules sachets This subset, as currently published, supports the NHS England QOF business rules for 2018-2019. This subset may contain invalid concepts.

Status

Subset Status :   
Supported
Subset Status Date :   
Mar 30, 2016
Owner (Organisation name) :   
NHS Digital

Purpose and Scope

Usage 1 :

   
Usage Type :    
Intended
Usage Description :    
Intended for secondary uses purposes. Management Information to support counts for establishing Quality and Outcomes Framework points used to determine Practice QOF payments. QOF Indicators Supported: Indicator OST002: The percentage of patients aged 50 or over and who have not attained the age of 75, with a fragility fracture on or after 1 April 2012, in whom osteoporosis is confirmed on DXA scan, who are currently treated with an appropriate bone-sparing agent. Indicator OST005: The percentage of patients aged 75 or over with a record of a fragility fracture on or after 1 April 2014 and a diagnosis of osteoporosis, who are currently treated with an appropriate bone-sparing agent. NICE clinical guidelines & advice: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended) TA161 http://www.nice.org.uk/guidance/ta161 These subsets are created using the XML format dm+d data and so within these subsets a small number of concepts are inactive (status 2 or 10) in the International Release. The origin of these inactive concepts is the native XML dm+d and they are now inactive in the new International Release due to natural movement and updating of the International Release content. Work is underway to update the dm+d concepts to the new International release identifiers; at this point this mismatch will be resolved. If using the dm+d in SNOMED CT format the International Release relationships will enable migration to the replacement concept. The subsets as published in the current release data are applicable to the QOF year 2018-2019.
Geographic Usage :    
England
Usage Category:    
 Quality Outcome Framework Prescribable


Scope :

   
Inclusion Criteria :   
Gender - not specified; Age group - any age; Sex - not specified
Subject Category :   
Prescribing; Chemicals and Drugs

Publication

Subset Release Category :   
UK Drug Extension
Language :   
en
Folder Name :   
QOF
File Name :   
der1_SubsetMembers_QOFNiceRecPresBoneSparAgents_GB1000001_YYYYMMDD

Subset Licence Type :   
IHTSDO SNOMED CT® Licence; UKTC SNOMED CT® Licence; Open Government Licence

Metadata Version :   
9.0
Last Updated :   
Feb 2, 2020

Related Links

Subset download with descriptions :

UK Drug Extension releases